AAV Gene Delivery: Precision Modeling for AD, PD, and ALS Research

Introduction

How do we faithfully recapitulate the complex pathologies of Alzheimer's, Parkinson's, or ALS in a laboratory setting to accelerate therapeutic discovery?

For decades, animal modeling relied heavily on transgenic lines or toxin-induced models. While valuable, these methods often lack the temporal control or the specific regional pathology observed in patients. Recently, Adeno-Associated Virus (AAV) vectors have emerged as a "magic scalpel" for neuroscientists. Due to their high safety profile, low immunogenicity, stable long-term expression, and broad tissue tropism, AAVs allow researchers to deliver specific genes directly into neural circuits, simulating the core pathological features of neurodegenerative diseases with unprecedented precision.

In this edition of the Cyagen Newsletter, we explore how AAV technology is being utilized to construct next-generation models for Alzheimer's, Parkinson's, and ALS.

Alzheimer’s Disease (AD): Modeling Aβ and Tau with AAV Vectors

Alzheimer’s disease (AD) is characterized clinically by dementia and pathologically by Amyloid-β (Aβ) deposition and Tau protein hyperphosphorylation. AAV stereotactic injection allows for the delivery of human mutant APP or Tau specifically to the hippocampus, triggering ectopic expression and mimicking AD pathology ^[1].

Figure 1. Comparison of Healthy vs. AD Brain Structure^[1]

Targeting Aβ Deposition, Modeling Aβ Deposition with AAV-APP/PSEN1 Delivery

A practical design for an Aβ-centric AAV model is to deliver human mutant APP and/or PSEN1 (a γ-secretase component) into the brain by stereotaxic injection. These mutations can increase production of aggregation-prone Aβ40 and Aβ42, where the Aβ42/Aβ40 ratio is highlighted as a key trigger for early AD pathology.

Case Study: Mickael Audrain et al. [2] utilized an AAVrh.10 vector to co-express human mutant APPSL and PS1M146L in the hippocampus of C57BL/6J mice.

The Result: The model achieved APP levels similar to human AD patients (avoiding artificial overexpression) while maintaining a high Aβ42/Aβ40 ratio. This successfully established an early-stage AD model driven by qualitative shifts in Aβ processing rather than quantitative overexpression.

Figure 2. APP production levels after 3 months post-injection^[2]

Figure 3. Aβ42/Aβ40 ratios after 3 months post-injection^[2]

Targeting Tau Phosphorylation in AAV-Based NHP Models

Moving beyond the amyloid hypothesis, AAV enables the exploration of Tauopathy in non-human primates (NHPs), offering high translational value.

Case Study (Rhesus Macaques): Jiang et al.^[3] delivered the human Tau gene via AAV9 into the hippocampus of rhesus macaques, and observed a range of AD-like features including Tau aggregation, neurofibrillary tangles, hippocampal atrophy, and cognitive decline, positioning this approach as a platform for drug screening in a brain system closer to humans.

Figure 4. Workflow schematic for primate model build & evaluation^[3]

Figure 5.3R/4R tau accumulation and Tau hyperphosphorylation^[3]

Figure 6: AD pathology features after AAV-Tau delivery to entorhinal cortex^[4]

Parkinson’s Disease (PD): Modeling α-Synuclein Progression

Parkinson’s disease (PD) is a common progressive neurodegenerative disorder and is characterized by progressive loss of dopaminergic neurons in the substantia nigra and misfolded α-synuclein aggregates. PD modeling strategies are often grouped into toxin models, genetic manipulation, and emerging in situ induction of pathological proteins. AAV delivery of α-synuclein into specific regions such as the substantia nigra or striatum is described as a way to reproduce core features including Lewy body–related pathology and disease progression.

Figure 7. Characteristics of Parkinson's Disease^[5]

Simulating Progressive Degeneration

Case Study: Researchers at Hannover Medical School ^[6] utilized the AAV/DJ serotype to deliver human α-synuclein in rats.
The Result: This was the first model to synchronize histopathology with progressive motor deficits. By 8 weeks, significant TH+ neuron loss was observed, followed by striatal fiber density reduction and formation of Ser129 phosphorylated α-synuclein inclusions.

Figure 8. Stereological assessment of dopaminergic neurons^[6]

Using AAV to Study Endogenous Compensation in Prodromal PD

Case Study: James B. Koprich et al. ^[7] used AAV1/2 to deliver human A53T α-synuclein.
The Result: They achieved progressive dopaminergic loss and axonopathy. Interestingly, by modulating the viral dose, the study revealed endogenous compensatory mechanisms within the dopaminergic system, offering a unique window into the prodromal phase of PD and potential neuroprotective interventions.

Figure 9. Dopaminergic Neuron Loss in Substantia Nigra^[7]

ALS Modeling: Dissecting Motor Circuits with AAV-TDP-43

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that selectively affects upper and lower motor neurons in the brain and spinal cord, leading to progressive weakness, muscle atrophy, and eventual respiratory failure. One highlighted hallmark includes intracellular TDP-43 aggregation, and modeling strategies often center on expressing familial ALS-associated mutant genes (e.g., SOD1, TDP-43, FUS, C9orf72) using AAV, delivered via intrathecal or intracerebroventricular routes to target motor neurons and reproduce motor neuron degeneration and functional loss.

Figure 10. ALS-FTD Mechanisms and Clinical Syndromes^[8]

Tracking Anterograde & Retrograde TDP-43 Spread in ALS

Case Study: Shintaro Tsuboguchi et al. ^[9] used AAV1 to express mutant TDP-43 in mice, revealing distinct propagation patterns.
The Result: The study reported muscle atrophy and forelimb paralysis (noted at 8 weeks post injection in the described setting), and over 12–24 weeks showed features such as corticospinal neuron loss, corticospinal tract (CST) axonal degeneration, and in vivo evidence of mutant TDP-43 anterograde propagation to oligodendrocytes along the CST with inclusions. In contrast, inducing TDP-43 in spinal motor neurons produced severe retrograde degeneration and neurogenic muscle atrophy with progressive motor dysfunction, supporting a model that captures molecular pathology, cellular degeneration, and behavioral phenotypes.

Figure 11. TDP-43 induced muscle atrophy and motor deficits.^[9]

Summary: Enhancing In Vivo Modeling via AAV Capsid & Promoter Innovation

Across AD, PD, and ALS, the examples above converge on a common theme: AAV enables targeted, circuit-aware introduction of disease drivers, making it possible to reproduce key molecular hallmarks and track downstream pathology and phenotypes in vivo. Looking forward, ongoing innovation in capsid engineering, tissue-specific promoters, and delivery strategies is expected to further expand what AAV can unlock for difficult neurodegenerative diseases.

Cyagen’s Featured Case Studies: AAV-Mediated Disease Modeling

References

1. Breijyeh, Z. and R. Karaman, Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules, 2020. 25(24).

2. Audrain, M., et al., Alzheimer's disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression. Mol Neurodegener, 2016. 11: p. 5.

3. Jiang, Z., et al., A nonhuman primate model with Alzheimer's disease-like pathology induced by hippocampal overexpression of human tau. Alzheimers Res Ther, 2024. 16(1): p. 22.

4. Beckman, D., et al., A novel tau-based rhesus monkey model of Alzheimer's pathogenesis. Alzheimers Dement, 2021. 17(6): p. 933-945.

5. Dovonou, A., et al., Animal models of Parkinson's disease: bridging the gap between disease hallmarks and research questions. Transl Neurodegener, 2023. 12(1): p. 36.

6. Kefalakes, E., et al., A holistic rat model to investigate therapeutic interventions in Parkinson's disease: viral induction of a slow-progressing motor phenotype, dopaminergic degeneration and early microglia neuroinflammation. Brain Res Bull, 2025. 230: p. 111464.

7. Koprich, J.B., et al., Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. PLoS One, 2011. 6(3): p. e17698.

8. Ilieva, H., M. Vullaganti, and J. Kwan, Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis. Bmj, 2023. 383: p. e075037.

9. Tsuboguchi, S., et al., TDP-43 differentially propagates to induce antero- and retrograde degeneration in the corticospinal circuits in mouse focal ALS models. Acta Neuropathol, 2023. 146(4): p. 611-629.